Theralase Technologies Inc.

Theralase Technologies Inc.

November 30, 2010 09:00 ET

Theralase Laser Technologies Announces Q3 Financials

TORONTO, ONTARIO--(Marketwire - Nov. 30, 2010) - Theralase Technologies Inc. (TSX VENTURE:TLT) announces its third quarter 2010 financials.

For the three months ended September 30, 2010, revenue decreased by 15% year over year with total revenue at $424,879, compared to $501,263 for the same period in 2009. Reasons for the decline were mainly attributable to an International distributor who was unable to abide by their contractual agreements.

For the three month period ending September 30, 2010 selling expenses increased by 61% due to increased spending on recent hires, travel and advertising used to expand our operations into the US and International markets.

For the period ending September 30, 2010 administrative expenses increased by 67% to $279,982 primarily as a result of increased expenditures on stock-based compensations, salaries (recent hires – production and accounting) and regulatory approval costs (CSA and CE).

Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated, "The net loss for the period ended September 30, 2010 was $402,236, which included $52,967 of non-cash expenses (amortization, stock-based compensation, foreign exchange and lease inducements). The company expenses the future product development costs of the TLC-2000 Biofeedback Therapeutic Laser and TLC-3000 Photo Dynamic Compound Technology from existing TLC-1000 Therapeutic Laser product sales, resulting in the overall net loss. The Company is expending funds to expand its sales and marketing footholds into the US and international markets.

The complete consolidated financial statements and MD&A for the three and nine months ending September 30, 2010 can be found at and

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology used in bio-stimulation and bio-destruction applications. The technology is popularized for its efficacious treatment of chronic pain, inflammation, wound care and the ability to attack specifically targeted cancer, bacteria, and viruses when used in the presence of the Company's patented Photodynamic Compounds.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

Contact Information